Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients
Betty K. Hamilton(Cleveland Clinic), Navneet S. Majhail(Sarah Cannon), Robert M. Dean(Cleveland Clinic), Ronald Sobecks(Cleveland Clinic), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Brad Pohlman(Cleveland Clinic), Aaron T. Gerds(Cleveland Clinic), Lisa Rybicki(Cleveland Clinic Lerner College of Medicine), Rabi Hanna(Cleveland Clinic), Arjun Law(University of Toronto), Donna Abounader(Cleveland Clinic), Hien K. Duong(Cleveland Clinic), Linda McLellan(Cleveland Clinic), Brian J. Bolwell(Cleveland Clinic), C. Lawrence(Cleveland Clinic), Brian T. Hill(Cleveland Clinic), M Kalaycio(Cleveland Clinic), Jane Dabney(Cleveland Clinic)
Cited by 32
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
|Biology of Blood and Marrow Transplantation|2015|409
Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation
|Biology of Blood and Marrow Transplantation|2011|363